You are viewing an expired study

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Rochester, New York 14642

  • Neoplasms, Metastatic

Purpose:

The standard therapy in cases such as yours is surgery, radiation therapy, chemotherapy or hormonal therapy alone or in combination. The main purpose of this study is to evaluate whether radiosurgery alone affects your quality and length of life. A second purpose of this study is to determine if the levels of special types of protein (called cytokines) found in the blood are related to your quality of life during your course of treatment and follow-up.


Study summary:

In this research study high dose stereotactic body radiation therapy will be directed at the site of metastasis. This treatment will be given once a day, 5 times a week (Monday through Friday) for one to four weeks depending on the location and size of the disease to be treated. Blood for the cytokine tests will be drawn before your therapy starts, weekly during therapy and at the follow-up visits as stated in the next paragraphs. Two to four tablespoons of blood will be removed each time.


Criteria:

Inclusion Criteria: Age ≥ 18 years KPS ≥ 70 Palliative: Disease most likely to be life limiting, is definable, and treatable to a sterilizing dose according to protocol criteria. The size of the lesion must be such that it can be safely treated to sterilizing radiation doses according to the rules in the protocol Previously treated lesions are not eligible unless the prescribed dose can be safely delivered. Previously enrolled patients can be retreated to new lesions if they still meet protocol requirements. Informed consent must be obtained. Pregnancy test must be negative for women of child bearing potential. Out of state patients are eligible, if communication with the referring physicians is expected to be adequate to address the primary aim. The secondary aim (blood cytokines) is optional for out-of-state patients. Exclusion Criteria: Technical inability to achieve required dose based on safe dose constraints required for radiosurgery Women who are pregnant or nursing.. Failure to meet inclusion requirements Contraindications to radiation. Patient should not be eligible for primary disease specific radiosurgical protocols


NCT ID:

NCT00178399


Primary Contact:

Principal Investigator
Michael Milano, MD PhD
University of Rochester


Backup Contact:

N/A


Location Contact:

Rochester, New York 14642
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.